Palvella Therapeutics, Inc. Earnings Per Share (Diluted)
Palvella Therapeutics, Inc. (PVLA) reported Earnings Per Share (Diluted) of -$1.52 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-04
- Palvella Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.52.
- Palvella Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.20.
- Palvella Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.03.
- Palvella Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-06-30 was -$0.86.
- Palvella Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$3.71.
- Palvella Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$7.83, a 460.83% decline from fiscal 2023.
- Palvella Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was $2.17.
- Palvella Therapeutics, Inc. earnings per share, diluted for fiscal 2021 was -$0.71.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.52 10-Q · filed 2026-08-04 | -$2.74 10-Q · filed 2026-08-04 | |||||
| 2026-03-31 | -$1.20 10-Q · filed 2026-05-07 | ||||||
| 2025-12-31 | -$3.71 10-K · filed 2026-03-31 | ||||||
| 2025-09-30 | -$1.03 10-Q · filed 2025-11-12 | -$2.63 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | -$0.86 10-Q · filed 2026-08-04 | -$1.60 10-Q · filed 2026-08-04 | |||||
| 2025-03-31 | -$0.74 10-Q · filed 2026-05-07 | ||||||
| 2024-12-31 | -$7.83 10-K · filed 2026-03-31 | ||||||
| 2024-09-30 | -$3.94 10-Q · filed 2025-11-12 | -$2.19 10-Q · filed 2024-11-13 | -$7.95 10-Q · filed 2025-11-12 | -$8.84 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$2.47 10-Q · filed 2025-08-14 | -$2.76 10-Q · filed 2024-08-14 | -$4.01 10-Q · filed 2025-08-14 | -$6.69 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | -$1.54 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | $2.17 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | -$8.70 10-Q · filed 2024-11-13 | -$18.33 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | $3.62 10-Q · filed 2024-08-14 | $0.05 10-Q · filed 2023-08-10 | -$9.08 10-Q · filed 2024-08-14 | -$0.11 10-Q · filed 2023-08-10 | |||
| 2022-06-30 | -$0.14 10-Q · filed 2023-08-10 | -$0.21 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | -$0.07 10-Q · filed 2022-05-11 | ||||||
| 2021-12-31 | -$0.71 10-K · filed 2022-03-02 | ||||||
| 2021-09-30 | -$0.24 10-Q · filed 2021-11-02 | -$0.58 10-Q · filed 2021-11-02 | |||||
| 2021-06-30 | -$0.25 10-Q · filed 2022-08-04 | -$0.33 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | -$0.07 10-Q · filed 2022-05-11 | ||||||
| 2020-12-31 | -$0.68 10-K · filed 2022-03-02 | ||||||
| 2020-09-30 | -$0.26 10-Q · filed 2021-11-02 | -$0.42 10-Q · filed 2021-11-02 | |||||
| 2020-06-30 | -$0.09 10-Q · filed 2021-08-05 | -$0.16 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |